

CELL THERAPEUTICS INC  
Form 8-K  
November 09, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 9, 2012 (November 5, 2012)**

**CELL THERAPEUTICS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Washington**  
**(State or Other Jurisdiction of**  
  
**Incorporation or Organization)**

**001-12465**  
**(Commission**  
  
**File Number)**

**91-1533912**  
**(I.R.S. Employer**  
  
**Identification No.)**

Edgar Filing: CELL THERAPEUTICS INC - Form 8-K

**3101 Western Avenue, Suite 600**

**Seattle, Washington**  
(Address of Principal Executive Offices)

**(206) 282-7100**

**98121**  
(Zip Code)

(Registrant's Telephone Number, Including Area Code)

**Not applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*(b) Departure of Certain Officers.*

On November 5, 2012, Cell Therapeutics, Inc. (the Company ) delivered notice to Daniel G. Eramian, the Executive Vice President, Corporate Communications of the Company, that his employment with the Company will terminate effective November 15, 2012.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELL THERAPEUTICS, INC.**

*(Registrant)*

By: /s/ James A. Bianco, M.D.  
James A. Bianco, M.D.  
President and Chief Executive Officer

Date: November 9, 2012